AIMD — Ainos, Inc.
NASDAQ · Technology · Scientific & Technical Instruments
About Ainos, Inc.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | — | -0.62 | — | $152,000 | — | -2.76% | -1.38% | -4.14% |
| 2026-05-13 | Q1 2026 | — | -0.41 | — | $161 | — | +0.58% | -12.28% | +11.70% |
| 2026-03-30 | Q4 2025 | — | -0.85 | — | $11,120 | — | -2.88% | +7.19% | +29.50% |
| 2025-11-13 | Q3 2025 | — | -0.64 | — | $2,167 | — | -14.34% | -25.97% | -16.67% |
| 2025-08-13 | Q2 2025 | — | -0.99 | — | $4,663 | — | +13.69% | +2.98% | +5.95% |
| 2025-03-07 | Q4 2024 | — | -0.26 | — | $0 | — | -5.89% | +6.54% | +1.76% |
| 2024-05-13 | Q1 2024 | — | -0.57 | — | $20,729 | — | -1.89% | -5.66% | -19.83% |
| 2024-03-08 | Q4 2023 | — | -1.36 | — | $19,904 | — | -20.00% | -40.98% | -49.27% |
Showing last 8 quarters.